X T L Biopharmaceuticals Ltd (NASDAQ:XTLB) traded down 1.5% on Thursday . The stock traded as low as $1.23 and last traded at $1.28, 526 shares were traded during trading. A decline of 73% from the average session volume of 1,921 shares. The stock had previously closed at $1.30.
Separately, ValuEngine upgraded X T L Biopharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd.
The company has a fifty day simple moving average of $1.36 and a two-hundred day simple moving average of $1.75. The company has a market cap of $6.68 million, a PE ratio of 8.67 and a beta of 0.96.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.
Recommended Story: How are capital gains distributions different for tax-deferred account?
Receive News & Ratings for X T L Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X T L Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.